Literature DB >> 17728610

FDG PET in lymphoma: the need for standardization of interpretation. An observer variation study.

Josée M Zijlstra1, Emile F Comans, Arthur van Lingen, Otto S Hoekstra, Chad M Gundy, Jan Willem Coebergh, Vivian Bongers.   

Abstract

OBJECTIVE: To measure and describe patterns of interobserver variation in visual interpretation of 18-FDG PET in malignant lymphoma.
METHODS: Eleven nuclear medicine physicians with different levels of PET experience independently reviewed 37 18F-FDG PET scans of lymphoma patients (10 obtained at presentation, 27 during or after therapy). They were requested to identify and localize suspicious lymphoma sites and to assign a stage to the baseline scans, and to interpret the remaining scans for the presence of viable lymphoma. Individual (extra-)nodal regions were assessed for the likelihood of malignancy as positive, negative or equivocal. These results were compared to expert readings after dichotomization in conservative and sensitive reading classifications.
RESULTS: Sixty-one percent and 56% (using sensitive and conservative reading, respectively) of the baseline scans were scored in accordance with the experts. Fourteen of the 27 scans obtained for therapy evaluation with viable tumour sites were scored in accordance with the experts in 82% and 94% of the patients, using conservative and sensitive reading, respectively. The 13 negative scans were scored in agreement with the experts in only 45% of the cases. False positivity pertained especially to the neck, periclavicular, axilla, mediastinum, lung and bone marrow. More experienced observers tended to have fewer false negative scores.
CONCLUSION: There are substantial disparities among nuclear medicine physicians' interpretations of FDG PET scans of lymphoma patients, which may affect patient care and results of multi-institutional clinical trials. A well-defined set of criteria is urgently needed to improve consistency.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17728610     DOI: 10.1097/MNM.0b013e3282eff2d5

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  20 in total

1.  Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.

Authors:  Sally F Barrington; Wendi Qian; Edward J Somer; Antonella Franceschetto; Bruno Bagni; Eva Brun; Helén Almquist; Annika Loft; Liselotte Højgaard; Massimo Federico; Andrea Gallamini; Paul Smith; Peter Johnson; John Radford; Michael J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-27       Impact factor: 9.236

Review 2.  FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma.

Authors:  Yvette L Kasamon; Richard L Wahl
Journal:  Curr Opin Oncol       Date:  2008-03       Impact factor: 3.645

3.  The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials.

Authors:  Ronald Boellaard; Wim J G Oyen; Corneline J Hoekstra; Otto S Hoekstra; Eric P Visser; Antoon T Willemsen; Bertjan Arends; Fred J Verzijlbergen; Josee Zijlstra; Anne M Paans; Emile F I Comans; Jan Pruim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-15       Impact factor: 9.236

4.  Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?

Authors:  Lale Kostakoglu; Heiko Schöder; Jeffrey L Johnson; Nathan C Hall; Lawrence H Schwartz; David J Straus; Ann S LaCasce; Sin-Ho Jung; Nancy L Bartlett; George P Canellos; Bruce D Cheson
Journal:  Leuk Lymphoma       Date:  2012-08-28

5.  Usefulness of (18)F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Patients with High-Grade Non-Hodgkin's Lymphoma.

Authors:  Yukyung Lee; Kyung Hoon Hwang; Junshik Hong; Jinny Park; Jae Hoon Lee; Jeong Yeal Ahn; Ji Hyun Kim; Haejun Lee; Seog Gyun Kim; Ji Young Shin
Journal:  Nucl Med Mol Imaging       Date:  2012-07-18

Review 6.  Positron emission tomographic scans in lymphoma: convention and controversy.

Authors:  Stephen M Ansell; James O Armitage
Journal:  Mayo Clin Proc       Date:  2012-06       Impact factor: 7.616

7.  Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma.

Authors:  Bouthaina S Dabaja; Jack Phan; Osama Mawlawi; L Jeffrey Medeiros; Carol Etzel; Fu-Wen Liang; Donald Podoloff; Yasuhiro Oki; Fredrick B Hagemeister; Hubert Chuang; Luis E Fayad; Jason Robert Westin; Ferial Shihadeh; Pamela K Allen; Christine F Wogan; Maria A Rodriguez
Journal:  Leuk Lymphoma       Date:  2013-05-07

Review 8.  From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Authors:  Richard L Wahl; Heather Jacene; Yvette Kasamon; Martin A Lodge
Journal:  J Nucl Med       Date:  2009-05       Impact factor: 10.057

9.  FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.

Authors:  Ronald Boellaard; Mike J O'Doherty; Wolfgang A Weber; Felix M Mottaghy; Markus N Lonsdale; Sigrid G Stroobants; Wim J G Oyen; Joerg Kotzerke; Otto S Hoekstra; Jan Pruim; Paul K Marsden; Klaus Tatsch; Corneline J Hoekstra; Eric P Visser; Bertjan Arends; Fred J Verzijlbergen; Josee M Zijlstra; Emile F I Comans; Adriaan A Lammertsma; Anne M Paans; Antoon T Willemsen; Thomas Beyer; Andreas Bockisch; Cornelia Schaefer-Prokop; Dominique Delbeke; Richard P Baum; Arturo Chiti; Bernd J Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

10.  Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.

Authors:  Yvette L Kasamon; Richard L Wahl; Harvey A Ziessman; Amanda L Blackford; Steven N Goodman; Caroline A Fidyk; Kathryn M Rogers; Javier Bolaños-Meade; Michael J Borowitz; Richard F Ambinder; Richard J Jones; Lode J Swinnen
Journal:  Biol Blood Marrow Transplant       Date:  2009-02       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.